Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Relapsed/Refractory Follicular Lymphoma 5 2025-09-03
TOCIACS : Efficacy and safety of Tocilizumab for acute chest syndrome treatment in paediatric and adult patients with sickle cell disease Recruiting

2023-505109-17-00 Sickle cell disease 5 2025-08-27
PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting

2024-514954-63-00 RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS 9 2025-08-20
A clinical trial for patients with relapsed or refractory multiple myeloma, using an experimental drug called ISB 2001 for the first time in… Recruiting

2023-507071-21-01 Relapsed/Refractory Multiple Myeloma 1 2025-08-14
Response-adaptive to Epcoritamab In FIrst Relapse: A Phase II, response-adaptive, Open-Label, Multicenter Study to Evaluate the Efficacy of … Recruiting

2024-514440-86-00 Relapse/Refractory Large B Cell Lymphoma 4 2025-08-04
A Study of ASTX030 (Cedazuridine in Combination with Azacitidine) in MDS, CMML, or AML Recruiting

2024-515098-93-00 Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic 5 2025-07-22
Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis Recruiting

2023-503634-50-01 Anemia in patients with chronic kidney disease on dialy 5 2025-07-22
Oral arsenic (ATO) in low-risk myelodysplastic syndromes (MDS) failing Erythropoiesis Stimulating Agents and Luspatercept Recruiting

2024-515311-22-00 low-risk Myelodysplastic Syndromes failing Erythropoies 3 2025-07-22
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department Recruiting

2023-504847-15-00 vaso-occlusive crisis due to sickle cell disease 5 2025-07-21
An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with… Recruiting

2024-519964-42-00 Thrombocythaemia 3 2025-07-02
Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector C… Recruiting

2024-515328-35-00 hematology 6 2025-07-02
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell… Recruiting

2024-519318-30-00 non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Ag 1 2025-06-25
Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting

2024-512696-12-00 BCR-ABL1+ Chronic Myeloid Leukemia 4 2025-06-24
A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit… Recruiting

2023-505834-84-00 relapsed and refractory primary diffuse large B-cell ly 10 2025-06-17
A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatri… Recruiting

2024-520167-13-00 Immunoglobulin A Nephropathy 5 2025-06-17
A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting

2023-510283-12-00 Sickle Cell Disease 7 2025-06-12
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM) Recruiting

2023-505788-35-00 Immune thrombocytopenia 4 2025-06-11
Atorvastatinbehandling til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythem… Recruiting

2024-518267-35-00 Blod cancer 4 2025-06-10
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium Recruiting

2023-503723-26-00 Patients undergoing allogeneic HSCT, for hematological 6 2025-06-04
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patie… Recruiting

2024-518071-58-00 Relapsed/refractory (r/r) acute myeloid leukemia (AML) 9 2025-05-16
A study with three treatments for higher-risk chronic myelomonocytic leukaemia. Recruiting

2024-511102-22-00 chronic myelomonocytic Leukemia 4 2025-05-13
A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A… Recruiting

2023-510155-37-00 Hypomethylating agent (HMA) naive myelodysplastic syndr 5 2025-05-08
A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting

2024-516009-22-00 myelodysplastic neoplasms/syndromes (MDS) 5 2025-04-30
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting

2024-516030-35-00 Multiple myeloma 5 2025-04-30